Table 2.
Baseline patient characteristics
| Characteristic | n = 67 |
|---|---|
| Age at diagnosis (y); median (range) | 15 (4-20) |
| Age at relapse/refractory disease (y); median (range) | 17 (8-21) |
| Sex | |
| Female | 34 (51%) |
| Male | 33 (49%) |
| Relapse or refractory | |
| Relapsed disease | 43 (64%) |
| Refractory disease | 24 (36%) |
| Timing of initial relapse | |
| Relapse <12 months | 27 (64%) |
| Relapse ≥12 months | 15 (36%) |
| Unknown | 1 |
| Stage at relapse | |
| I | 2 (3%) |
| II | 31 (47%) |
| III | 7 (11%) |
| IV | 26 (39%) |
| Unknown | 1 |
| B symptoms | 13 (19%) |
| Bulk disease | 20 (30%) |
| Extranodal disease | 23 (35%) |
| Salvage regimens before ASCT | |
| 1 | 50 (75%) |
| 2 | 12 (18%) |
| 3 | 5 (7%) |
| Treatment with brentuximab before ASCT | |
| At any time | 46 (69%) |
| Immediately before ASCT | 41 (61%) |
| PET response before ASCT | |
| Negative | 45 (69%) |
| Positive | 20 (31%) |
| Unknown | 2 |
| BMT conditioning | |
| BEAM | 40 (60%) |
| CBV | 10 (15%) |
| Other∗ | 17 (25%) |
| RT given in salvage | 30 (45%) |
BEAM, carmustine, etoposide, cytarabine, melphalan; CBV, carmustine, cyclophosphamide, etoposide.
∗
Other BMT conditioning regimens included gemcitabine, busulfan, melphalan, and vorinostat (8 patients); busulfan, gemcitabine, and melphalan (4 patients); etoposide and melphalan (3 patients); and cyclophosphamide and etoposide (2 patients).